Laslitec IV infusion 1.5mg, containing Rasburicase (genetically recombined), is manufactured by Sanofi. This injectable drug, with YJ code 3959415F1025 and standard 1.5mg x 1 bottle (with dissolving solution), is used to manage high uric acid levels (hyperuricemia) in cancer patients undergoing chemotherapy.
Laslitec IV infusion 1.5mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →